A Phase 3 interventional study of Azilsartan medoxomil and Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. in Hypertension, sponsored by Takeda. Completed at 45 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-04.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 10th largest by enrollment, is one of 3 that started in 2007, is one of 10 in phase 3, and was the 1st registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →
azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2007.
This study's enrollment of 418 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 837 across the 11 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
15 studies in Essential Hypertension by Takeda: none open now, none under way, none of them phase 3. Of 15 finished, 14 (93%) have results posted.
Among the 15 studies in Essential Hypertension by Takeda, this one is the 12th largest by enrollment, is one of 4 that started in 2007, is one of 12 in phase 3, and was the 1st registered.
Takeda’s Essential Hypertension studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 15 in Essential Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure.
A major component of blood pressure regulation is the renin-angiotensin-aldosterone system, a system of hormone-mediated feedback interactions that results in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. AII is the principal pressor agent of the renin-angiotensin-aldosterone system with a myriad of effects on the cardiovascular system and on electrolyte homeostasis. Two receptors for angiotensin II have been identified. Angiotensin II type 1 (AT1) receptors are located predominantly in vascular smooth muscle, where activation by angiotensin II results in vasoconstriction, hypertrophic proliferation, and inflammation. In contrast, stimulation of angiotensin II type 2 (AT2) receptors by angiotensin II results in vasodilation, antiproliferative effects, and other effects that are opposite from those of AT1 receptor stimulation.
Drugs that modulate the renin-angiotensin-aldosterone system are used commonly worldwide for the treatment of hypertension. Of these, some block the synthesis of angiotensin II by inhibiting angiotensin-converting enzyme inhibitors, while others inhibit the action of angiotensin II by binding directly to the AT1 receptor (angiotensin II receptor blockers), thereby allowing blood vessels to dilate, resulting in a reduction in blood pressure. The effects of angiotensin II receptor blockers on other conditions in which the renin-angiotensin-aldosterone system plays a significant role, such as congestive heart failure, post-myocardial infarction management, and diabetic nephropathy, also are being investigated.
Takeda Global Research \& Development Center, Inc. is developing TAK-491 (azilsartan medoxomil) to treat mild to moderate essential hypertension. Nonclinical studies have indicated that azilsartan medoxomil is an antagonist of the AT1 receptor subtype.
This study consists of 2 phases. The first phase will be a 26-week, open-label, multicenter phase to evaluate the safety and tolerability of TAK-491 in participants with essential hypertension. Investigators were instructed to manage participants according to a protocol-specified treatment algorithm to achieve target blood pressure. All participants who completed the open-label phase then were randomized into a 6-week double-blind, placebo-controlled (azilsartan medoxomil [maintained at the final dose from the open-label phase] or placebo, in addition to their current other antihypertensive medications including chlorthalidone, as applicable) reversal phase to evaluate maintenance/durability of azilsartan medoxomil -mediated blood pressure reduction, as well as potential rebound following the cessation of azilsartan medoxomil.
Study participation is anticipated to be about 8.5 Months. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations and electrocardiograms.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
This study's enrollment of 418 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Browse Essential Hypertension studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Azilsartan medoxomil
Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Drug: Placebo
All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks. Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit.
Also known as: TAK-491, Edarbi
Drug page: Azilsartan medoxomil
Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
Also known as: TAK-491, Edarbi
Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32
The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.
Time frame: Double-blind Baseline (Week 26) and Week 32.
Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32
The change in sitting clinic systolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26.. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.
Time frame: Double-blind Baseline (Week 26) and Week 32.
Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26
The change from baseline in sitting clinic diastolic blood pressure measured at final visit or week 26.
Time frame: Baseline and Week 26.
Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26
The change from baseline in sitting clinic systolic blood pressure measured at final visit or week 26.
Time frame: Baseline and Week 26.
Number of Participants With Adverse Events During the Open-Label Phase
Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for serious adverse event (SAE). A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.
Time frame: Baseline to Week 26
Number of Participants With Adverse Events in the Double-Blind Baseline Phase
Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for SAE. A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.
Time frame: Double-blind Baseline/Week 26 to Week 32
Participants enrolled at 51 investigative sites in Argentina, Mexico and the United States from 22 June 2007 to 08 May 2009.
| Milestone | Azilsartan Medoxomil QD - Open Label Phase | Azilsartan Medoxomil QD - Double-Blind Reversal Phase | Placebo QD - Double-Blind Reversal Phase |
|---|---|---|---|
| Started | 418 | 0 | 0 |
| Completed | 299 | 0 | 0 |
| Not completed | 119 | 0 | 0 |
| Withdrew: Adverse event | 27 | 0 | 0 |
| Withdrew: Protocol violation | 18 | 0 | 0 |
| Withdrew: Lost to follow-up | 24 | 0 | 0 |
| Withdrew: Withdrawal by subject | 37 | 0 | 0 |
| Withdrew: Other | 6 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 |
| Withdrew: Physician decision | 4 | 0 | 0 |
| Milestone | Azilsartan Medoxomil QD - Open Label Phase | Azilsartan Medoxomil QD - Double-Blind Reversal Phase | Placebo QD - Double-Blind Reversal Phase |
|---|---|---|---|
| Started | 0 | 148 | 151 |
| Completed | 0 | 137 | 145 |
| Not completed | 0 | 11 | 6 |
| Withdrew: Adverse event | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 |
The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.
| mmHg | Azilsartan Medoxomil QD - Double Blind Reversal Phase | Placebo QD - Double Blind Reversal Phase |
|---|---|---|
| Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32 | 0.14 ± 0.726 | 7.92 ± 0.712 |
The change in sitting clinic systolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26.. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.
| mmHg | Azilsartan Medoxomil QD - Double Blind Reversal Phase | Placebo QD - Double Blind Reversal Phase |
|---|---|---|
| Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32 | 0.59 ± 1.121 | 12.97 ± 1.098 |
The change from baseline in sitting clinic diastolic blood pressure measured at final visit or week 26.
| mmHg | Azilsartan Medoxomil QD - Open Label Phase |
|---|---|
| Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26 | -15.76 ± 11.912 |
The change from baseline in sitting clinic systolic blood pressure measured at final visit or week 26.
| mmHg | Azilsartan Medoxomil QD - Open Label Phase |
|---|---|
| Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26 | -23.01 ± 20.657 |
Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for serious adverse event (SAE). A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.
| participants | Azilsartan Medoxomil QD - Open Label Phase |
|---|---|
| Serious Adverse Events | 8 |
| Treatment Emergent Adverse Events | 226 |
Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for SAE. A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.
| participants | Azilsartan Medoxomil QD - Double Blind Reversal Phase | Placebo QD - Double Blind Reversal Phase |
|---|---|---|
| Serious Adverse Events | 0 | 1 |
| Treatment Emergent Adverse Events | 42 | 38 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Azilsartan Medoxomil QD - Open Label | — | 8/418 (1.9%) | 60/418 (14.4%) |
| Azilsartan Medoxomil QD - Double-Blind Reversal Phase | — | 0/148 (0%) | 5/148 (3.4%) |
| Placebo QD - Double-Blind Reversal Phase | — | 1/151 (0.7%) | 8/151 (5.3%) |
| Event | Azilsartan Medoxomil QD - Open Label | Azilsartan Medoxomil QD - Double-Blind Reversal Phase | Placebo QD - Double-Blind Reversal Phase |
|---|---|---|---|
| Hypertensive crisisVascular disorders | 0/418 | 0/148 | 1/151 |
| Acute coronary syndromeCardiac disorders | 1/418 | 0/148 | 0/151 |
| Diabetic retinopathyEye disorders | 1/418 | 0/148 | 0/151 |
| Eye haemorrhageEye disorders | 1/418 | 0/148 | 0/151 |
| PancreatitisGastrointestinal disorders | 1/418 | 0/148 | 0/151 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/418 | 0/148 | 0/151 |
| Hip fractureInjury, poisoning and procedural complications | 1/418 | 0/148 | 0/151 |
| DehydrationMetabolism and nutrition disorders | 1/418 | 0/148 | 0/151 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/418 | 0/148 | 0/151 |
| ConvulsionNervous system disorders | 1/418 | 0/148 | 0/151 |
| Event | Azilsartan Medoxomil QD - Open Label | Azilsartan Medoxomil QD - Double-Blind Reversal Phase | Placebo QD - Double-Blind Reversal Phase |
|---|---|---|---|
| DizzinessNervous system disorders | 36/418 | 3/148 | 3/151 |
| HeadacheNervous system disorders | 30/418 | 5/148 | 8/151 |
| Age, Customized(participants) | Azilsartan Medoxomil QD - Open Label Phase |
|---|---|
| <45 years | 89 |
| Between 45 and 64 years | 287 |
| ≥ 65 years | 42 |
| Age, Customized(percentage of participants) | Azilsartan Medoxomil QD - Open Label Phase |
|---|---|
| <45 years | 21.3 |
| Between 45 and 64 years | 68.7 |
| ≥ 65 years | 10.0 |
| Sex/Gender, Customized(participants) | Azilsartan Medoxomil QD - Open Label Phase |
|---|---|
| Female | 210 |
| Male | 208 |
The record gives a start of Jun 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azilsartan medoxomil